# A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

> **NCT05579691** · PHASE2 · COMPLETED · sponsor: **Larimar Therapeutics, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Friedreich Ataxia

## Interventions

- **BIOLOGICAL:** CTI-1601
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05579691
- **Lead sponsor:** Larimar Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-21
- **Primary completion:** 2023-12-04
- **Final completion:** 2023-12-04
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05579691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05579691, "A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT05579691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*